Fredun Pharmaceuticals Limited has scheduled a revised earnings conference call to discuss its financial performance for the quarter ended Q4FY26. The meeting is set to take place on June 10, 2026, at 11:00 a.m., providing stakeholders with an opportunity to review the company's quarterly results and operational outlook.

The announcement was made in compliance with Regulation 30 read with sub-para 15, Para A Part A Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will be led by the company's Managing Director, Fredun Medhora.

Participants can join the discussion using the universal dial-in numbers provided by the company. Registration is required to access the conference via the Diamond Pass link. Stakeholders are advised to dial in approximately 10 minutes prior to the scheduled start time to ensure timely connection.

Conference Call Details

Key Participants

• Fredun Medhora: Managing Director

The conference call facilitator, Kirin Advisors, noted that certain statements made during the session may constitute forward-looking statements. These are subject to risks and uncertainties, including changes in the economic environment, and actual results may differ materially from those expressed or implied.

Fredun Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026, on May 25, 2026. The company reported strong financial performance with substantial growth in revenue, profitability, and operating margins across both the full year and the fourth quarter. The Board of Directors recommended a final dividend of ₹0.70 per equity share and approved a 2:1 bonus issue, signaling confidence in future growth.

Financial Performance

For the fiscal year 2025-26, the company reported a standalone net profit of ₹33.21 crore, compared to ₹20.81 crore in the previous year. Total income from operations rose to ₹639.12 crore from ₹456.27 crore in the prior year. The fourth quarter also reflected robust year-on-year growth, with net profit climbing to ₹11.07 crore from ₹7.07 crore in the same period of the previous year. Quarterly revenue grew to ₹213.05 crore compared to ₹167.41 crore in the corresponding prior-year period.

Key Financial Metrics

The following table summarizes the standalone financial performance for the year ended March 31, 2026, alongside the quarterly comparison:

Operating Performance

The company's quarterly operating performance showed a marked improvement, with Q4 EBITDA rising to ₹29.13 crore from ₹17.44 crore in the same period of the previous year. The EBITDA margin expanded significantly to 13.67% from 10.42% year-on-year, reflecting improved operational efficiency and better cost management during the quarter.

Board Decisions

The Board of Directors recommended a final dividend of ₹0.70 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved the issuance of bonus shares to shareholders and warrant holders in the ratio of 2:1, meaning shareholders will receive two fully paid-up bonus equity shares of ₹10 each for every one existing equity share held. The record date for determining eligibility will be intimated in due course.

Corporate Actions

In other corporate decisions, the board approved an increase in the authorized share capital from ₹10 crore to ₹50 crore, subject to shareholder approval. The company also appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. The statutory auditors issued an unmodified opinion on the standalone and consolidated financial results.